Table 1:

Baseline Characteristics.

Participant Number	Gender	Age	Weight (kg)	Height (cm)	Ethnicity	HCV Genotype	Mode of Acquiring HCV	HIV(Antiretro viral Therapy)	HCV Treatment Outcome*
2	Female	23	59.0	166	Caucasian	3a	IDU	No	SVR
4	Male	47	76.0	180.5	Caucasian	1a	IDU	No	Relapse
8	Male	31	61.1	170	Asian	1a	IDU	Yes (nevirapine, TDF, FTC)	Relapse
9	Male	73	68.1	178	Caucasian	1a	SE, MSM	Yes (etravirine, lamivudine, raltegravir)	Relapse
10	Male	39	64.0	171	Caucasian	1a	IDU	Yes (raltegravir, TDF, FTC)	Relapse
12	Male	31	94.6	186	Caucasian	1a	SE, MSM	Yes (rilpivirine, TDF, FTC)	Relapse
13	Male	44	68.0	179	Asian	1a	IDU	Yes (efarivirenz, TDF, FTC)	Relapse
14	Male	49	77.3	185	Caucasian	1a	SE, MSM	Yes (TDF, FTC)	Relapse
15	Male	54	91.1	181	Caucasian	1a	SE, MSM	Yes (efavirenz, TDF, FTC)	Relapse
17	Male	53	94.3	171	Hispanic	3a	SE, MSM	Yes (rilpivirine, TDF, FTC)	Non-response‡
18	Male	30	79.4	190	Caucasian	1a	IDU	Yes (TDF, FTC)	Non-response
19	Male	45	90.5	186	Caucasian	3a	IDU	No	Relapse

^*Non-response, signifies that HCV RNA was quantifiable at end of treatment (EOT); Relapse, signifies quantifiable HCV RNA, confirmed as homologous virus, at post-treatment week 12 despite unquantifiable HCV RNA at EOT;

^‡Spontaneous clearance of virus more than 12 weeks post treatment observed; IDU, injecting drug use; MSM, men who have sex with men. HIV, human immunodeficiency virus; SVR, sustained virological response; SE, sexual exposure; TDF, tenofovir disoproxil fumarate; FTC, emtricitabine.